JP2852985B2 - ホルモン性避妊のための排卵抑制剤 - Google Patents
ホルモン性避妊のための排卵抑制剤Info
- Publication number
- JP2852985B2 JP2852985B2 JP4021079A JP2107992A JP2852985B2 JP 2852985 B2 JP2852985 B2 JP 2852985B2 JP 4021079 A JP4021079 A JP 4021079A JP 2107992 A JP2107992 A JP 2107992A JP 2852985 B2 JP2852985 B2 JP 2852985B2
- Authority
- JP
- Japan
- Prior art keywords
- hormonal
- hormone
- component
- units
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003054 hormonal effect Effects 0.000 title claims abstract description 50
- 239000003433 contraceptive agent Substances 0.000 title claims description 29
- 239000000262 estrogen Substances 0.000 claims abstract description 48
- 229940011871 estrogen Drugs 0.000 claims abstract description 42
- 239000000583 progesterone congener Substances 0.000 claims abstract description 33
- 229940088597 hormone Drugs 0.000 claims abstract description 31
- 239000005556 hormone Substances 0.000 claims abstract description 31
- 230000016087 ovulation Effects 0.000 claims abstract description 13
- 238000004806 packaging method and process Methods 0.000 claims abstract description 3
- 230000027758 ovulation cycle Effects 0.000 claims description 20
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 12
- 229960002568 ethinylestradiol Drugs 0.000 claims description 12
- 230000037406 food intake Effects 0.000 claims description 12
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 8
- 229930182833 estradiol Natural products 0.000 claims description 8
- 229960005309 estradiol Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000035800 maturation Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 3
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims description 3
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 3
- 229960001616 chlormadinone acetate Drugs 0.000 claims description 3
- 239000003687 estradiol congener Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229960004400 levonorgestrel Drugs 0.000 claims description 3
- 229960001652 norethindrone acetate Drugs 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- 229960000978 cyproterone acetate Drugs 0.000 claims description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229960001390 mestranol Drugs 0.000 claims description 2
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims 1
- -1 dezogestrel Chemical compound 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 8
- 238000012856 packing Methods 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 description 15
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229960004766 estradiol valerate Drugs 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940083544 estradiol 2 mg Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4104385:5-41 | 1991-02-09 | ||
| DE4104385A DE4104385C1 (enExample) | 1991-02-09 | 1991-02-09 | |
| DE41043855-41 | 1991-02-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0558909A JPH0558909A (ja) | 1993-03-09 |
| JP2852985B2 true JP2852985B2 (ja) | 1999-02-03 |
Family
ID=6424973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4021079A Expired - Lifetime JP2852985B2 (ja) | 1991-02-09 | 1992-02-06 | ホルモン性避妊のための排卵抑制剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5280023A (enExample) |
| EP (1) | EP0499348B2 (enExample) |
| JP (1) | JP2852985B2 (enExample) |
| AT (1) | ATE136781T1 (enExample) |
| AU (2) | AU669327B2 (enExample) |
| BR (1) | BR9204121A (enExample) |
| CA (1) | CA2079002C (enExample) |
| DE (2) | DE4104385C1 (enExample) |
| DK (1) | DK0499348T4 (enExample) |
| ES (1) | ES2086644T5 (enExample) |
| FI (1) | FI98888C (enExample) |
| GR (1) | GR3019833T3 (enExample) |
| HU (1) | HU218663B (enExample) |
| NO (1) | NO179696C (enExample) |
| RU (1) | RU2091069C1 (enExample) |
| WO (1) | WO1992013539A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4224534A1 (de) * | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
| DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| DE4321957C2 (de) * | 1993-07-01 | 1995-09-28 | Marika Dr Med Ehrlich | Verwendung eines hormonalen Mittels zur Therapie der Akne |
| DE4344405C2 (de) * | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| DE4405591C1 (de) * | 1994-02-22 | 1995-07-20 | Hesch Rolf Dieter Prof Dr Med | Mittel zur postmenopausalen Hormonsubstitution |
| DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE19504227C2 (de) * | 1995-02-09 | 1999-04-29 | Klaus Dr Med Umbreit | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| US20050032756A1 (en) * | 1995-10-28 | 2005-02-10 | Michael Dittgen | Multistage preparation for contraception based on natural estrogens |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
| US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
| US6451778B1 (en) | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
| AU3888697A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
| US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
| US6479475B1 (en) | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| DK1007052T3 (da) * | 1997-08-27 | 2005-01-31 | Ortho Mcneil Pharm Inc | Kombinationer af endometrisk skånende progesteroner og endometrisk atrofiserende progesteroner med östrogener ved oral svangerskabs-forebyggelse |
| US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
| US7989436B2 (en) | 2003-07-23 | 2011-08-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and pharmaceutical formulations comprising the same |
| US6660726B2 (en) * | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
| US7459445B2 (en) * | 2000-03-10 | 2008-12-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and topical pharmaceutical formulations of the same |
| US6855703B1 (en) | 2000-03-10 | 2005-02-15 | Endeavor Pharmaceuticals | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| NZ533242A (en) * | 2001-12-05 | 2007-11-30 | Duramed Pharmaceuticals Inc | Oral extended regime contraceptive package |
| US6992075B2 (en) | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| WO2004091535A2 (en) * | 2003-04-11 | 2004-10-28 | Barr Laboratories, Inc. | Methods of administering estrogens and progestins |
| US7855190B2 (en) * | 2003-07-16 | 2010-12-21 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| DE102004026669A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| DE102004026671A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
| DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| US20060100566A1 (en) * | 2004-11-05 | 2006-05-11 | Women's Medical Research Group, Llc | Apparatus and method for the treatment of dysmenorrhea |
| WO2006084082A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
| US7704984B2 (en) * | 2005-04-22 | 2010-04-27 | Warner Chilcott Company, Llc | Extended estrogen dosing contraceptive regimen |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6615481A (enExample) † | 1966-11-02 | 1968-05-03 | ||
| US3639600A (en) † | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
| US3733407A (en) * | 1971-08-25 | 1973-05-15 | Syntex Corp | Menopause treatment |
| DE2431704A1 (de) * | 1974-07-02 | 1976-01-22 | Asche Ag | Stufenkombinationspraeparate per kontrazeption |
| DE2645307A1 (de) * | 1976-10-05 | 1978-04-06 | Schering Ag | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
| NL8001593A (nl) * | 1980-03-18 | 1981-10-16 | Akzo Nv | Meerfasisch combinatiepreparaat voor orale anticonceptie. |
| US4921843A (en) * | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
| HU214598B (hu) * | 1987-09-24 | 1998-04-28 | Jencap Research Ltd | Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására |
| EP0368373A1 (en) * | 1988-10-13 | 1990-05-16 | Akzo Nobel N.V. | Multi-phase contraceptive preparation |
-
1991
- 1991-02-09 DE DE4104385A patent/DE4104385C1/de not_active Expired - Lifetime
-
1992
- 1992-01-22 EP EP92250018A patent/EP0499348B2/de not_active Expired - Lifetime
- 1992-01-22 DE DE59205986T patent/DE59205986D1/de not_active Expired - Fee Related
- 1992-01-22 AT AT92250018T patent/ATE136781T1/de not_active IP Right Cessation
- 1992-01-22 DK DK92250018T patent/DK0499348T4/da active
- 1992-01-22 ES ES92250018T patent/ES2086644T5/es not_active Expired - Lifetime
- 1992-02-06 JP JP4021079A patent/JP2852985B2/ja not_active Expired - Lifetime
- 1992-02-07 RU SU925053226A patent/RU2091069C1/ru active
- 1992-02-07 CA CA002079002A patent/CA2079002C/en not_active Expired - Fee Related
- 1992-02-07 WO PCT/DE1992/000081 patent/WO1992013539A1/de not_active Ceased
- 1992-02-07 BR BR929204121A patent/BR9204121A/pt not_active Application Discontinuation
- 1992-02-07 AU AU11910/92A patent/AU669327B2/en not_active Ceased
- 1992-02-07 HU HU9203197A patent/HU218663B/hu not_active IP Right Cessation
- 1992-02-10 US US07/833,294 patent/US5280023A/en not_active Expired - Fee Related
- 1992-10-05 NO NO923874A patent/NO179696C/no not_active IP Right Cessation
- 1992-10-07 FI FI924519A patent/FI98888C/fi active
-
1993
- 1993-10-06 US US08/132,287 patent/US5510341A/en not_active Expired - Fee Related
-
1996
- 1996-04-09 AU AU50538/96A patent/AU692376B2/en not_active Ceased
- 1996-05-06 GR GR960401208T patent/GR3019833T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9204121A (pt) | 1993-06-08 |
| US5510341A (en) | 1996-04-23 |
| US5280023A (en) | 1994-01-18 |
| ATE136781T1 (de) | 1996-05-15 |
| FI924519L (fi) | 1992-10-07 |
| HUT64229A (en) | 1993-12-28 |
| HU218663B (hu) | 2000-10-28 |
| NO923874D0 (no) | 1992-10-05 |
| AU669327B2 (en) | 1996-06-06 |
| DE4104385C1 (enExample) | 1992-08-13 |
| JPH0558909A (ja) | 1993-03-09 |
| HU9203197D0 (en) | 1992-12-28 |
| EP0499348A1 (de) | 1992-08-19 |
| NO179696B (no) | 1996-08-26 |
| CA2079002C (en) | 1998-07-28 |
| DK0499348T3 (da) | 1996-08-12 |
| WO1992013539A1 (de) | 1992-08-20 |
| AU692376B2 (en) | 1998-06-04 |
| NO923874L (no) | 1992-10-05 |
| FI98888C (fi) | 1997-09-10 |
| ES2086644T5 (es) | 2002-11-16 |
| GR3019833T3 (en) | 1996-08-31 |
| FI924519A0 (fi) | 1992-10-07 |
| RU2091069C1 (ru) | 1997-09-27 |
| FI98888B (fi) | 1997-05-30 |
| CA2079002A1 (en) | 1992-08-10 |
| DE59205986D1 (de) | 1996-05-23 |
| EP0499348B2 (de) | 2002-03-27 |
| EP0499348B1 (de) | 1996-04-17 |
| ES2086644T3 (es) | 1996-07-01 |
| NO179696C (no) | 1996-12-04 |
| AU1191092A (en) | 1992-09-07 |
| AU5053896A (en) | 1996-06-27 |
| DK0499348T4 (da) | 2002-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2852985B2 (ja) | ホルモン性避妊のための排卵抑制剤 | |
| USRE36247E (en) | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | |
| RU2169566C2 (ru) | Средство и способ для гормональной контрацепции и/или для лечения акне | |
| KR100352571B1 (ko) | 배합호르몬피임약제 | |
| USRE43916E1 (en) | Composition for contraception | |
| US6312722B1 (en) | Pharmaceutical combined preparation, kit and method for hormonal contraception | |
| US7538099B1 (en) | Antiprogestin method and kit for reducing side effects associated with low dosage HRT, oral contraception and regulating menses | |
| US20070207945A1 (en) | Extended cycle multiphasic oral contraceptive method | |
| EP0686037A4 (en) | HORMON REPLACEMENT THERAPY | |
| EA016625B1 (ru) | Способ контроля прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов | |
| JPH07509454A (ja) | ホルモン避妊のための排卵抑止剤 | |
| KR19980703702A (ko) | 호르몬 피임법용 제약학상 복합 제제 | |
| CN101189015A (zh) | 延长的雌激素定量给药避孕疗法 | |
| JPH09500112A (ja) | ざ瘡治療用ホルモン剤及びその使用法 | |
| RU2127112C1 (ru) | Эстроген (прогестин)антипрогестиновый способ пероральной контрацепции и регулирования менструации, фармацевтическая композиция и набор лекарственных средств | |
| Levine | Nondaily hormonal contraceptives: Establishing a fit between product characteristics and patient preferences | |
| US20080280861A1 (en) | Method of Female Contraception and a Kit For Use Therein | |
| CN107875388A (zh) | 对延长的激素避孕方案中突破性出血的控制 | |
| MXPA98007513A (en) | Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo | |
| MXPA96004440A (en) | Preparation of a pharmaceutical combination for oven contraception | |
| MXPA98000026A (en) | Combined pharmaceutical preparation, equipment and method for hormo contraception | |
| HK1077743B (en) | Composition for contraception |